Lantheus (NASDAQ:LNTH) Posts Quarterly Earnings Results, Beats Expectations By $0.25 EPS

Lantheus (NASDAQ:LNTH) issued its quarterly earnings results on Thursday. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25, FiscalAI reports. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same quarter in the prior year, the business posted $1.57 earnings per share. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year.

Lantheus Price Performance

Shares of LNTH stock traded down $0.12 during trading hours on Friday, reaching $100.95. The company’s stock had a trading volume of 2,079,590 shares, compared to its average volume of 1,643,055. The firm’s 50 day simple moving average is $104.09 and its 200-day simple moving average is $87.98. The company has a market capitalization of $6.57 billion, a price-to-earnings ratio of 24.38 and a beta of -0.03. Lantheus has a fifty-two week low of $49.67 and a fifty-two week high of $111.86. The company has a quick ratio of 2.64, a current ratio of 3.06 and a debt-to-equity ratio of 0.43.

Hedge Funds Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of LNTH. Smartleaf Asset Management LLC grew its stake in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the period. Vident Advisory LLC raised its holdings in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after purchasing an additional 230 shares in the last quarter. Parallel Advisors LLC lifted its position in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares during the period. Orion Porfolio Solutions LLC lifted its position in Lantheus by 3.9% during the second quarter. Orion Porfolio Solutions LLC now owns 10,010 shares of the medical equipment provider’s stock valued at $819,000 after buying an additional 377 shares during the period. Finally, Osterweis Capital Management Inc. bought a new stake in shares of Lantheus during the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of recent analyst reports. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and cut their target price for the company from $110.00 to $102.50 in a research report on Monday. CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday. Citizens Jmp reaffirmed a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a research report on Monday, June 29th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a research note on Wednesday, July 29th. Finally, Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and decreased their target price for the company from $125.00 to $102.50 in a report on Monday. Five analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Lantheus currently has an average rating of “Hold” and an average price target of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.